AB
ABOS.US Acumen Pharmaceuticals Inc
- Market cap
- USD 15.8M
- P/E
- -
- P/B
- 0.48x
- ROE
- -303.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ABOS.US undervalued?
Graham numberThe Graham number of Acumen Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Acumen Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Acumen Pharmaceuticals Inc yet.
Acumen Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirn…
Full company profileAcumen Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Acumen Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.70M | 1.44M | 1.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -6.88M | -6.56M | -12.3M | -169K | -42.3M | -178K | -184K | - |
| Operating Income | -7.81M | -7.91M | -19.6M | -45.2M | -61.1M | -114M | -124M | -106M |
| EBITDA | 119K | -7.91M | -101M | -42.7M | -51.6M | -98.1M | -117M | -101M |
| Net Income | -7.91M | -7.33M | -101M | -42.9M | -52.4M | -102M | -121M | -105M |
| EPS | -0.28 | -0.26 | -2.63 | -1.06 | -1.08 | -1.71 | -2.00 | -1.45 |
| Balance Sheet | ||||||||
| Total Assets | 7.32M | 44.4M | 230M | 197M | 310M | 239M | 123M | 85.6M |
| Total Liabilities | 18.7M | 63.0M | 5.15M | 7.81M | 43.2M | 57.2M | 52.4M | 51.0M |
| Shareholders' Equity | -11.4M | -18.6M | 225M | 189M | 267M | 182M | 70.4M | 34.6M |
| Cash & Short-term Investments | 6.55M | 43.8M | 194M | 178M | 244M | 172M | 117M | 78.6M |
| Total Debt | - | - | 201K | 105K | 28.5M | 29.7M | 31.3M | 26.3M |
| Cash Flow | ||||||||
| Operating Cash Flow | -6.82M | -7.45M | -18.0M | -35.2M | -43.1M | -86.2M | -116M | -91.8M |
| Capital Expenditure | 40.0K | 40.0K | 40.0K | 161K | 21.0K | 16.0K | 88.0K | 0.00 |
| Free Cash Flow | -6.82M | -7.45M | -18.0M | -35.3M | -43.1M | -86.2M | -116M | -91.8M |
| Ratios | ||||||||
| ROE | - | - | -44.7% | -22.7% | -19.6% | -56.3% | -172.3% | -303.7% |
| ROA | -108.0% | -16.5% | -43.7% | -21.8% | -16.9% | -42.8% | -98.8% | -122.8% |
| Net Profit Margin | -465.9% | -510.1% | -7,006.0% | - | - | - | - | - |
| Debt to Equity | - | - | 0.00x | 0.00x | 0.11x | 0.16x | 0.44x | 0.76x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Acumen Pharmaceuticals Inc dividends
Acumen Pharmaceuticals Inc has not paid dividends in the last 7 fiscal years.
Who owns Acumen Pharmaceuticals Inc
- Insiders 6.79%
- Institutions 67.20%
- Public & others 26.01%
- Shares outstanding 72.3M
- Free float 37.1M
Top funds holding ABOS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Franklin Biotechnology Discv A(acc)USD | 1.48M | 2.04% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.26M | 1.75% | +12.91% | Sep 2026 |
| iShares Russell 2000 ETF | 1.14M | 1.57% | 0.00% | Oct 2026 |
| Franklin Biotechnology Discovery A | 826K | 1.14% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 514K | 0.71% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 430K | 0.59% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 274K | 0.38% | +1.31% | Sep 2026 |
| Fidelity Extended Market Index | 206K | 0.28% | -10.00% | Sep 2026 |
| iShares Micro-Cap ETF | 144K | 0.20% | 0.00% | Oct 2026 |
| A4Investments SICAV SIF ACCI IlanaA2EURH | 130K | 0.18% | +18.18% | Oct 2026 |
| Schwab Small Cap Index | 115K | 0.16% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 109K | 0.15% | 0.00% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 88.3K | 0.12% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 85.5K | 0.12% | 0.00% | Oct 2026 |
| Bridgeway Ultra-Small Company | 75.0K | 0.10% | 0.00% | Jun 2026 |
| Fidelity Total Market Index | 73.5K | 0.10% | -0.05% | Sep 2026 |
| Fidelity Small Cap Value Index | 69.9K | 0.10% | +6.11% | Aug 2026 |
| Fidelity Series Total Market Index | 66.6K | 0.09% | 0.00% | Sep 2026 |
| Nuveen Small Cap Blend Idx R6 | 63.4K | 0.09% | 0.00% | Aug 2026 |
| Bridge Builder Small Cap Fund | 54.2K | 0.07% | 0.00% | Oct 2026 |
Top institutions holding ABOS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 21.0M | 29.02% | 0.00% | Jun 2026 |
| Sands Capital Ventures, LLC | 3.72M | 5.14% | 0.00% | Jun 2026 |
| BlackRock Inc | 2.49M | 3.44% | +1,296.38% | Jun 2026 |
| Alyeska Investment Group, L.P. | 2.45M | 3.39% | 0.00% | Jun 2026 |
| Franklin Templeton Inc | 2.31M | 3.19% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 2.11M | 2.92% | -2.09% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.67M | 2.31% | +11.01% | Jun 2026 |
| Knollwood Investment Advisory LLC | 1.63M | 2.25% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.14M | 1.58% | +174.33% | Jun 2026 |
| Ikarian Capital, LLC | 1.05M | 1.46% | 0.00% | Jun 2026 |
| Hudson Bay Capital Management LP | 955K | 1.32% | -1.44% | Jun 2026 |
| Pathstone Holdings LLC | 859K | 1.19% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 675K | 0.93% | +42.43% | Jun 2026 |
| Two Sigma Investments LLC | 623K | 0.86% | +17.35% | Jun 2026 |
| State Street Corp | 601K | 0.83% | +295.79% | Jun 2026 |
| Northern Trust Corp | 361K | 0.50% | +379.64% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 324K | 0.45% | +11.13% | Sep 2026 |
| Vanguard Portfolio Management, LLC | 321K | 0.44% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 291K | 0.40% | +46.19% | Jun 2026 |
| Bank of America Corp | 275K | 0.38% | -14.19% | Jun 2026 |
Acumen Pharmaceuticals Inc company profile
- Company name
- Acumen Pharmaceuticals Inc
- Ticker
- ABOS.US
- Exchange
- USA Stocks
- Listed since
- Jul 1, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 60
- Fiscal year end
- December
- Address
- 1210-1220 Washington St., Newton, MA, United States, 02465
- Phone
- 617 344 4190
- Website
- acumenpharm.com
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Acumen Pharmaceuticals Inc management
10- Mr. Daniel J. O'Connell M.B.A.CEO & Director · born 1970
- Dr. James Doherty Ph.D.President & Chief Development Officer · born 1968
- Mr. Matt ZugaCFO & Chief Business Officer
- Dr. Grant A. Krafft Ph.D.Co-Founder
- Dr. Caleb E. Finch Ph.D.Co-Founder
- Dr. William L. Klein Ph.D.Co-Founder
- Mr. Russell Barton M.S.Chief Operating Officer · born 1959
- Ms. Kelly CarranzaSenior Vice President of Finance & Accounting and Corporate Controller
- Ms. Alex Braun M.B.A.VP & Head of Investor Relations
- Mr. Derek M. Meisner Esq., J.D.Chief Legal Officer & Corporate Secretary · born 1971